ICD-10-CM 2027 diagnosis code
D61.810Antineoplastic chemotherapy induced pancytopenia
D61.810 is a valid, billable ICD-10-CM code for antineoplastic chemotherapy induced pancytopenia. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.
Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About D61.810
D61.810 is the ICD-10-CM diagnosis code for antineoplastic chemotherapy induced pancytopenia. It belongs to category D61 (other aplastic anemias and other bone marrow failure syndromes), block D60-D64 (aplastic and other anemias and other bone marrow failure syndromes) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Within D61.81 (pancytopenia), D61.810 is specifically for antineoplastic chemotherapy induced pancytopenia. Related codes cover other drug-induced pancytopenia (D61.811) and other pancytopenia (D61.818).
The conditions in its Excludes2 note aren't part of D61.810, but may be coded alongside it if the patient has both: aplastic anemia due to antineoplastic chemotherapy (D61.1).
As a secondary diagnosis it is an MCC (major complication or comorbidity), which can move an inpatient stay into the highest-paying "with MCC" MS-DRG of its family, unless the principal diagnosis excludes it.
In MS-DRG v44.0, it is part of the grouping logic for DRG 808 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with MCC, relative weight 2.1705), DRG 809 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with CC, relative weight 1.2262) and DRG 810 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders without CC/MCC, relative weight 1.075), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
Before ICD-10, this condition was coded in ICD-9-CM as 284.11 (antineoplastic chemotherapy induced pancytopenia).
Coding notes
- aplastic anemia due to antineoplastic chemotherapy (D61.1)
Notes that apply from higher levels
Instructions written at a parent level also apply to D61.810.
› From D61.81 Pancytopenia
- pancytopenia (due to) (with) aplastic anemia (D61.9)
- pancytopenia (due to) (with) bone marrow infiltration (D61.82)
- pancytopenia (due to) (with) congenital (pure) red cell aplasia (D61.01)
- pancytopenia (due to) (with) hairy cell leukemia (C91.4-)
- pancytopenia (due to) (with) human immunodeficiency virus disease (B20.-)
- pancytopenia (due to) (with) leukoerythroblastic anemia (D61.82)
- pancytopenia (due to) (with) myeloproliferative disease (D47.1)
- pancytopenia (due to) (with) myelodysplastic syndromes (D46.-)
› From D61 Other aplastic anemias and other bone marrow failure syndromes
- neutropenia (D70.-)
Broader instructions also apply from Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.
Alphabetic index entries
1 entriesTerms in the official ICD-10-CM index that lead to D61.810.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 16 · Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders
- 808Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with MCCRW 2.1705
- 809Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with CCRW 1.2262
- 810Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders without CC/MCCRW 1.075
ICD-9-CM equivalent
Converter →- 284.11Antineoplastic chemotherapy induced pancytopeniaexact
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about D61.810
Is D61.810 billable?
- Yes. D61.810 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can D61.810 be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict D61.810 as a principal diagnosis.
Is D61.810 a CC or MCC?
- D61.810 is an MCC (major complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.
What DRG does D61.810 group to?
- D61.810 is used in the MS-DRG v44.0 logic for MS-DRG 808 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with MCC), MS-DRG 809 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with CC) and MS-DRG 810 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for D61.810?
- The CMS General Equivalence Mappings map D61.810 to ICD-9-CM 284.11.